Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR

Steven M. Rowe, Susanna A. McColley, Ernst Rietschel, Xiaolei Li, Scott C. Bell, Michael W. Konstan, Gautham Marigowda, David Waltz, Michael P. Boyle, behalf of the VX09-809-102 Study Group

Research output: Contribution to journalArticle

Abstract

Rationale: In a prior study, lumacaftor/ivacaftor treatment (<28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function. Objectives: To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a longer duration in a cohort of patients heterozygous for F508del-CFTR. Methods: Patients aged 18 years or older with a confirmed CF diagnosis and percent predicted FEV1 (ppFEV1) of 40 to 90 were randomized to lumacaftor/ivacaftor (400 mg/250 mg every 12 h) or placebo daily for 56 days. Primary outcomes were change in ppFEV1 at Day 56 and safety. Other disease markers were evaluated. Measurements and Main Results: Of 126 patients, 119 (94.4%) completed the study. Lumacaftor/ivacaftor was well tolerated, although chest tightness and dyspnea occurred more frequently with active treatment than with placebo (27.4% vs. 14.3% and 14.5% vs. 6.3%, respectively). Mean (SD) ppFEV1 values at baseline were 62.9 (14.3) in the active treatment group and 60.1 (14.0) in the placebo group. Absolute changes in ppFEV1 (least squares mean [SE]) at Day 56 were 20.6 (0.8) percentage points in the active treatment group and 21.2 (0.8) percentage points in the placebo group (P = 0.60). CF respiratory symptom scores in the active treatment group improved by a mean of 5.7 points versus a decrease of 20.8 in the placebo group (P,0.01). No changes in body mass index occurred. Changes from baseline in sweat chloride (least squares mean [SE]) at Day 56 were211.8 (1.3) mmol/L in the active treatment group and 20.8 (1.2) mmol/L in the placebo group (P,0.0001). Conclusions: Sweat chloride and respiratory symptom scores improved with lumacaftor/ivacaftor, though no meaningful benefit was seen in ppFEV1 or body mass index in patients heterozygous for F508del-CFTR.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalAnnals of the American Thoracic Society
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Adverse events
  • Percent predicted forced expiratory volume in 1 second
  • Sweat chloride

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR'. Together they form a unique fingerprint.

  • Cite this

    Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., Boyle, M. P., & behalf of the VX09-809-102 Study Group (2017). Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Annals of the American Thoracic Society, 14(2), 213-219. https://doi.org/10.1513/AnnalsATS.201609-689OC